-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WWk0zETQMcG9eo8mtzXCQQGe7Jw/qq6W2Dy/Mt6N/O9hKlaLAVI0W4fWfMFq7n0g
 tsEIMRdpWYpGIpKtx1NaLQ==

<SEC-DOCUMENT>0001035704-04-000565.txt : 20040927
<SEC-HEADER>0001035704-04-000565.hdr.sgml : 20040927
<ACCEPTANCE-DATETIME>20040927133722
ACCESSION NUMBER:		0001035704-04-000565
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040927
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20040927
DATE AS OF CHANGE:		20040927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHARMION CORP
		CENTRAL INDEX KEY:			0001203866
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50447
		FILM NUMBER:		041046716

	BUSINESS ADDRESS:	
		STREET 1:		2525 28TH STREET
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		720 564 9100
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d18704e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">





<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date of Report (Date of earliest event reported)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>September&nbsp;27, 2004</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 24pt"><B>Pharmion Corporation</B>
<HR size="1" noshade width="100%" align="center">
<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-50447</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>84-1521333</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File<BR>
Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">2525 28th Street, Boulder, Colorado
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">80301</TD>
</TR>

<TR style="font-size: 1px">
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="left">Registrant&#146;s telephone number, including area code
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">720-564-9100</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P>&nbsp;
<DIV align="center" style="font-size: 10pt"><HR size="1" noshade width="100%" align="center">
(Former name or former address if changed since last report)</DIV>


<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">






<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><B><U>Item</U> 2.02</B>&nbsp;</TD>
    <TD><B>Financial Statements, Pro Forma Financial Information and Exhibits</B></TD>
</TR>
</TABLE>



<P align="left" style="margin-left:8%; font-size: 10pt">(c)&nbsp;Exhibit&nbsp;99.1 &#151; Press Release dated September&nbsp;27, 2004.



<P align="left" style="margin-left:8%; font-size: 10pt">This exhibit is furnished pursuant to Item&nbsp;12 and shall not be
deemed to be &#147;filed.&#148;


<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap><B><U>Item</U> 9.01</B>&nbsp;</TD>
    <TD><B>Disclosure of Results of Operations and Financial Condition</B></TD>
</TR>
</TABLE>



<P align="left" style="margin-left:10%; font-size: 10pt">On September&nbsp;27, 2004, the
Pharmion Corporation issued a
press release updating the
Company&#146;s 2004 sales and
earnings guidance. A copy of
the press release is attached
as Exhibit&nbsp;99.1 to this
Current Report on Form 8-K.
The information in this Form
8-K and the exhibit attached
hereto shall not be deemed
&#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities
Exchange Act of 1934 (the
&#147;Exchange Act&#148;) or otherwise
subject to the liabilities of
that section, nor shall it be
deemed incorporated by
reference in any filing under
the Securities Act of 1933 or
the Exchange Act, except as
shall be expressly set forth
by specific reference in such
filing.


<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3">PHARMION CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>Date: 9-27-04&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000"><B>/s/ Erle T. Mast</B>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Erle T. Mast&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated September&nbsp;27, 2004 updating the Company&#146;s 2004 sales and earnings guidance.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">3
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d18704exv99w1.htm
<DESCRIPTION>PRESS RELEASE DATED SEPTEMBER 27, 2004 UPDATING THE COMPANY'S 2004 SALES AND EARNINGS GUIDANCE.
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt"><B>EXHIBIT 99.1</B>



<P align="left" style="font-size: 10pt">FOR RELEASE UPON RECEIPT ON SEPTEMBER 27, 2004



<P align="left" style="font-size: 10pt">Contact:<BR>
Breanna Burkart/Anna Sussman<BR>
Directors, Investor Relations and Corporate Communications<BR>
Pharmion Corporation<BR>
720-564-9150


<P align="center" style="font-size: 14pt"><B>Pharmion Corporation Increases Vidaza Sales Guidance</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BOULDER, Colo., September&nbsp;27, 2004 &#151; Pharmion Corporation (NASDAQ: PHRM)
today reported that it has increased sales guidance for Vidaza for the second
half of 2004 to a range of $40-45&nbsp;million, from its previous range of $20-27
million, based on greater than anticipated sales in the initial months of its
Vidaza launch.

<P align="left" style="font-size: 10pt">Vidaza<SUP>TM</SUP> (azacitidine for injectable suspension) was launched in the U.S. on
July&nbsp;1, 2004 after receiving a full approval in May from the U.S. Food and Drug
Administration (FDA)&nbsp;for the treatment of all five subtypes of Myelodysplastic
Syndromes (MDS). These subtypes include: refractory anemia (RA)&nbsp;or refractory
anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or
thrombocytopenia or requiring transfusions), refractory anemia with excess
blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T),
and chronic myelomonocytic leukemia (CMMoL).

<P align="left" style="font-size: 10pt">&#147;We are pleased that physicians are choosing to use Vidaza in their treatment
of MDS,&#148; said Patrick Mahaffy, Pharmion&#146;s president and chief executive
officer. &#147;While we caution that it is still too early in the launch to
estimate the longer-term sales of Vidaza, it is evident from our sales to date
and our interactions with physicians that Vidaza represents a potentially
important new treatment option for this very difficult-to-treat disease.&#148;


<P align="left" style="font-size: 10pt"><B>2004 Financial Outlook</B>


<DIV align="left" style="font-size: 10pt">Pharmion is increasing its net sales expectations for 2004 to a range of
$111-119&nbsp;million, up from previous guidance of $91-$101&nbsp;million, based on
increased expectations for sales of Vidaza. The Company now estimates total
Vidaza sales for the second half of 2004 will be in a range of $40-45&nbsp;million,
an increase from previous guidance of $20-27&nbsp;million. Thalidomide sales
guidance remains in a range of $58-61&nbsp;million for 2004. With the revised
guidance for Vidaza sales, the Company now estimates its net loss for 2004 to
be in a range of $(0.90) &#151; $(1.10) per share, compared to its previous guidance
range of a net loss of $(1.40) &#151; (1.60) per share.
</DIV>

<P align="center" style="font-size: 10pt">-more-



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>Pharmion Increases Vidaza Sales Guidance for 2004<BR>
Page Two</B>


<P align="left" style="font-size: 10pt"><B>About MDS</B>


<DIV align="left" style="font-size: 10pt">MDS is a bone marrow disorder characterized by the production of abnormally
functioning, immature blood cells. The highest prevalence of MDS is in patients
over 60&nbsp;years of age. According to the American Cancer Society and the Aplastic
Anemia and MDS International Foundation, there are an estimated 10,000-30,000
new cases of MDS in the United States each year. Survival ranges from six
months to many years for the different subtypes of MDS. MDS can result in death
from bleeding and infection in the majority of patients, and transformation to
acute myelogenous leukemia (AML)&nbsp;occurs in up to 40&nbsp;percent of patients. The
prognosis for patients transforming to AML is exceptionally poor.
</DIV>

<P align="left" style="font-size: 10pt"><B>About Pharmion:</B>

<DIV align="left" style="font-size: 10pt">Pharmion is a pharmaceutical company focused on acquiring, developing and
commercializing innovative products for the treatment of hematology and
oncology patients in the U.S., Europe and additional international markets. For
additional information about Pharmion, please visit the Company&#146;s website at
www.pharmion.com.
</DIV>

<P align="left" style="font-size: 10pt"><B>Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: </B>This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are based on
current expectations and involve a number of known and unknown risks and
uncertainties that could cause Pharmion&#146;s future results, performance or
achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include the status
and timing of regulatory approvals for Thalidomide Pharmion 50mg and Vidaza;
the impact of competition from other products under development by Pharmion&#146;s
competitors; the regulatory environment and changes in the health policies and
structure of various countries; acceptance and demand for new pharmaceutical
products and new therapies, uncertainties regarding market acceptance of
products newly launched, currently being sold or in development; Pharmion&#146;s
ability to successfully acquire rights to develop and commercialize additional
pharmaceutical products; fluctuations in currency exchange rates, and other
factors that are discussed in Pharmion&#146;s filings with the U.S. Securities and
Exchange Commission. Forward-looking statements speak only as of the date on
which they are made, and Pharmion undertakes no obligation to update publicly
or revise any forward-looking statement, whether as a result of new
information, future developments or otherwise.


<P align="center" style="font-size: 10pt"># # #




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
